LENZ Therapeutics

LENZ Therapeutics

LENZ Therapeutics operates as a pharmaceutical company focused on commercializing VIZZ (aceclidine ophthalmologic solution) 1.44% in the United States. The firm grew from a clinical-stage entity into a commercial organization upon the FDA approval of VIZZ for presbyopia. Co-founder James McCollum shaped the early direction, and Eef Schimmelpennink has led as President and CEO since March 2021. The company's revenue center and observable value-driving asset is VIZZ, which targets the inevitable loss of near vision in adults over 45. LENZ's strategy concentrates on a single-product ophthalmology franchise. VIZZ competes in the presbyopia market against surgical solutions and another pharmaceutical drop. The company deploys capital toward manufacturing scale-up, a direct specialty sales force under VP of Sales Domenick Porfidia, and the build-out of a commercial operations team. LENZ has stated it is pursuing international licensing partnerships to expand VIZZ globally. The management team draws from Allergan, Alcon, and Novartis ophthalmology units. Marc Odrich as Chief Medical Officer leads post-approval medical affairs, while Kris Gambelin manages regulatory and clinical operations. LENZ structured its public-company position through a merger with Graphite Bio. Board members include RA Capital Management principal Zach Scheiner and former Alcon CEO Jeff George, who serves as chairman. The executive team has expanded to include recently created roles in AI enablement and commercial analytics under Jaime Elledge and Ahmad Chaudhri. In August 2023, Graphite Bio appointed Kimberlee Drapkin as CEO ahead of its combination with LENZ, creating the public vehicle for the ophthalmology asset. LENZ is structurally distinct as a single-product public biotech operating without a pipeline beyond its lead indication. The company has not disclosed plans for follow-on molecules or diversification into other ophthalmic conditions. Governance resides with a board chaired by Jeff George and substantially influenced by RA Capital's board designee, placing operational control alongside specialist healthcare investors rather than a founding family or multi-strategy manager.